Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 2

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

NCT05463224 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 2
Started
2023-01-04
Last updated
2026-07-28

Condition(s) studied

NSCLC

Investigational drug(s) / intervention(s)

Lazertinib group

Lazertinib group: Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)

Study summary

The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer which is not amenable to treatment with a curative aim (e.g. surgery or radiation). Patients who underwent curative intent surgery or definitive CRT and experience recurrence after 6 months are eligible. * Stage IIIC or IV by AJCC 8th edition * Confirmed EGFR mutations (exon 19 deletion, L858R)(The result from both cell-free DNA or tissue-based DNA from the local test is allowed.) * Age of 19 or more. * Performance status of Eastern Cooperative Oncology Group 0 to 2. * Expected minimum life expectancy of 12 weeks * Adequate organ function. * Available to provide the adequate tissue and blood for the genomic tests- At least 15 unstained slide and 20 cc of blood at baseline (mandatory) and disease progression. * Agreed to perform re-biopsy at the timepoint of disease progression. * At least two weeks after the chemotherapy * Female subjects must either be of non-reproductive potential * Subject willing and able to comply with the protocol * Signed written informed consent Exclusion Criteria: * Previously treatment with any kind of EGFR TKI (Previously chemotherapy treated patients is allowed) * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug. (allowed for participation if investigator decided that previous malignancy is cured and not need for any additional treatment) * Uncontrolled central nervous system metastases- patient with asymptomatic brain metastases or CNS symptom manageable with TKI and evaluated by investigator can be enrolled. * Spinal cord compression, leptomeningeal carcinomatosis * Uncontrolled systemic illness, including uncontrolled hypertension, active bleeding, or active infection * Radiotherapy with a wide field of radiation within 2 weeks or radiotherapy with a limited field of radiation (localized radiotherapy or gamma knife surgery) for palliation within 1 week * Any unresolved toxicities from prior therapy, greater than CTCAE grade 1 * Mean QT interval corrected for heart rate (QTc) ≥ 470 ms * No measurable lesion * Unable to swallow the product due to refractory nausea, vomiting or chornic gastrointestinal disease.

Primary outcome measure(s)

  • progression-free survival — through study completion, an average of 18.0 month
    C1D1 until the date of objective disease progression or death
  • Resistance mechanism analysis — Screening, Discontiunuation Visit
    The mutation profile of baseline and at the timepoint of resistance will be evaluated using tissue and cfDNA

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul Gangnamgu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05463224 on ClinicalTrials.gov ↗ ← All trials in South Korea